Indeed, we find that low levels of PDCD4 correlate with high levels of Bcl-xL in both de novo GBM patient tumors and in established GBM cell lines and that high Bcl-xL correlates with poor progression and patient survival. The gene discussed is BCL2L1; the disease is glioblastoma.